Document is current
Any future updates will be listed below
-
Authors
Kennedy, Amber L.
Hiscock, Richard J.
Vollenhoven, Beverley J.
Stern, Catharyn J.
Gurrin, Lyle C.
Osianlis, Tiki
Kink, Aleah
Walker, Susan P.
Cheong, Jeanie L. Y.
Quach, Jon L.
Wilkinson, David
McBain, John
Green, Mark P.
Atkinson, Jessica A.
Agresta, Franca
Baohm, Susan P.
Tong, Stephen
Hastie, Roxanne
Lindquist, Anthea C.
-
Funding
Funding for this research was provided by:
Mercy Perinatal
Australian Government
Ferring Pharmaceuticals
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 20 February 2025
First Online: 1 April 2025
Declarations
:
: Each data custodian provided contractual approval for data access and linkage. Given the retrospective and deidentified nature of this study, individual participant informed consent was not required. Ethical approval for the project was obtained from Mercy, Monash Health and Melbourne IVF Health Human Research Ethics Committees.
: Not applicable.
: All authors have completed the ICMJE uniform disclosure form (). Most authors have declared that no competing interests exist. A.L.K has received various education sponsorship and honoraria from Merck PTY LTD and Organon Pharma PTY LTD unrelated to this project. B.V has a paid role as a member of the Therapeutic Good Administration. T.O, B.V, F.A and K.S own shares in respective IVF companies (Newlife IVF, Monash IVF, Virtus Health and Melbourne IVF). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
